Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14327800 | 1.00 | CTSK (0.51) | CTSKCTSSMAPTCYP3A4CYP2C19 | |
| SCHEMBL13168624 | 1.00 | CTSK (0.51) | CTSKCTSSMAPTCYP3A4CYP2C19 | |
| SCHEMBL15355250 | 0.92 | CYP3A4 (0.58) | CTSKCTSSMAPTCYP3A4CYP2C19 | |
| SCHEMBL13208214 | 0.87 | CTSK (0.50) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL14803932 | 0.87 | CTSK (0.50) | CTSKCTSSMAPTCYP3A4CYP2C19 | |
| SCHEMBL887419 | 0.87 | PPARG (0.42) | CTSKCTSSMAPTCYP3A4CYP2C19 | |
| SCHEMBL13079942 | 0.87 | CTSK (0.50) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL13051340 | 0.87 | CTSK (0.50) | CTSKCTSSMAPTCYP3A4CYP2C19 | |
| SCHEMBL887428 | 0.85 | CTSS (0.44) | CTSKCTSSMAPTGABRB1GABRB2 | |
| SCHEMBL887425 | 0.85 | CYP1A2 (0.45) | CTSKCTSSMAPTCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142639-A1 | Process for production of amines | SMS, CCNT1, PEAK1 | CTSK 4517/4885CTSS 4383/4885MAPT 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.